Lung Cancer Diagnostics Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

Lung Cancer Diagnostics Industry Overview

Uncontrolled cell proliferation can result in the development of a mass known as a tumor, which is the cause of lung cancer. Although most lung cancers originate from the cells lining the larger and smaller airways (bronchi and bronchioles), lung cancers can typically start in any section of the lung. For this reason, lung cancers are also known as bronchogenic cancers or bronchogenic carcinomas. Approximately 90% of lung cancers are caused by tobacco use, making cigarette smoking the primary cause of the disease. Lung illness, a history of lung cancer, air pollution, and a person's genetic predisposition are other reasons. The location and extent of the tumor determine the symptoms of lung cancer. Lung cancer frequently manifests as dysphagia, headaches, chest pain, coughing up blood, and shortness of breath.

The increasing prevalence of lung cancer, the introduction of technical improvements pertaining to accuracy, and the expanding awareness levels among the public across all regions are driving the growth of the global lung cancer diagnostic market. Additionally, throughout the forecast period, the availability of government and private funding for research and development to create better tumor diagnostic tools is anticipated to propel the growth of the lung cancer diagnostics market. For example, Roche Diagnostics introduced the first in vitro diagnostic immunohistochemistry (IHC) test in June 2019 to enhance lung cancer diagnosis. However, it is projected that the negative consequences linked to imaging technologies and the high cost of diagnostics will impede market expansion.

Growth Drivers for the Lung Cancer Diagnostics Market

Raising awareness of screening and early detection

People are more likely to seek out preventative healthcare measures like routine tests as public education campaigns raise awareness of potential risk factors for lung cancer, such as smoking and environmental pollution. Furthermore, the advocacy work of different medical groups can raise awareness even more, which will encourage healthcare professionals to give lung cancer screening and diagnosis top priority.

A groundbreaking program to transform lung cancer screening and detection in Florida will be launched in October 2024 by the Florida Lung Health Coalition and DELFI Diagnostics, with backing from RadNet, Inc. and the American Lung Association.

Rising Prevalence of Lung Cancer

Advancements in diagnostic technologies are revolutionizing lung cancer detection, significantly improving accuracy and enabling earlier diagnosis. Liquid biopsy, a non-invasive test, allows for the detection of genetic mutations and tumor markers from blood samples, offering a quicker, less risky alternative to traditional biopsy. Next-generation sequencing (NGS) provides a comprehensive analysis of genetic mutations and tumor profiles, helping to identify personalized treatment options for patients. Additionally, advanced imaging technologies like PET and CT scans are enhancing early detection by providing detailed, high-resolution images of lung tissue, enabling the identification of even small tumors or abnormalities that might be missed with traditional methods. These innovations are improving diagnostic accuracy, reducing false positives, and leading to better patient outcomes through earlier intervention and more targeted treatments.

Advancements in Diagnostic Technologies

Lung cancer detection is being revolutionized by advances in diagnostic technologies, which greatly increase accuracy and allow for earlier diagnosis. A quicker and less dangerous option to standard biopsy is liquid biopsy, a non-invasive test that can identify tumor markers and genetic abnormalities in blood samples. NGS offers a thorough examination of tumor profiles and genetic alterations, assisting in the development of individualized treatment plans for patients. Furthermore, by offering precise, high-resolution pictures of lung tissue, sophisticated imaging technologies like PET and CT scans are improving early diagnosis by making it possible to spot even tiny tumors or anomalies that conventional techniques could overlook. By enabling earlier intervention and more focused treatments, these advancements are increasing diagnostic precision, decreasing false positives, and improving patient outcomes.

Challenges in the Lung Cancer Diagnostics Market

High Cost of Advanced Technologies

One major obstacle to the widespread use of lung cancer diagnostics is the expensive expense of sophisticated diagnostic methods including liquid biopsies, next-generation sequencing (NGS), and PET/CT scans. Even though these technologies provide better accuracy and early detection capabilities, they are frequently too costly, especially in healthcare settings with limited resources. Many healthcare facilities, particularly those in low- and middle-income nations, may not be able to afford the expenses involved in creating, maintaining, and using these sophisticated instruments. Furthermore, patient access is restricted due to the expensive cost, which may cause delays in diagnosis or a dependence on less precise, conventional techniques. The market for lung cancer diagnostics depends on initiatives to lower costs, increase cost-effectiveness, and improve accessibility in order to guarantee wider adoption and improved patient results.

Limited Access to Screening

Access to routine lung cancer screening programs is still a significant obstacle, especially in low- and middle-income nations. Despite advances in technology, many areas lack the financial support, infrastructure, and resources required to carry out extensive screening programs. Frequent screening, which is essential for enhancing survival rates and detecting problems early, frequently necessitates access to sophisticated diagnostic equipment like CT scans, which may not be easily accessible in these places. Funding for cancer screening programs may also be further restricted in resource-constrained healthcare systems where other urgent health concerns may take precedence. In many areas, there is also a lack of public knowledge regarding the significance of early detection, which leads to the underutilization of screening services. Due to this restricted access, lung cancer mortality rates rise and diagnosis times are prolonged, decreasing the likelihood of effective treatment.

Imaging tests are a critical component of the lung cancer diagnostics market

Imaging tests stand among the forefront sections of the global lung cancer diagnostics market. This is due to their pivotal function in early detection and correct assessment of tumors. Technologies like computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI) offer specified visualization of lung tissue, helping in tumor localization, staging, and remedy planning. Their non-invasive nature and capability to stumble on abnormalities at early phases contribute to their recognition. Imaging assessments are vital in lung cancer diagnosis, thanks to non-stop technological improvements that enhance resolution and specificity. This has solidified their function as a leading section in the worldwide market.

Non-small cell lung cancer is a key focus in diagnostics

Non-Small Cell Lung Cancer (NSCLC) holds one of the prominent positions in the global lung cancer diagnostics market. This is due to its high incidence and numerous treatment alternatives. NSCLC drives considerable demand for diagnostic assessments, which include imaging, biomarker evaluation, and histopathology. Its heterogeneous nature necessitates a precise prognosis and staging for top-quality remedy choice, spurring innovation in diagnostic technology. Moreover, advancements in centered treatments and immunotherapies tailor-made to particular NSCLC subtypes further underscore the importance of correct diagnosis. As NSCLC continues to pose a substantial healthcare burden, its diagnostic stage remains a cornerstone of the global lung cancer diagnostics market.

Hospital-associated labs play a crucial role in global lung cancer diagnostics

Hospital Associated Labs is one of the most used in the global lung cancer diagnostics market. This is due to their accessibility and comprehensive services. Situated in healthcare centers, these labs offer short turnaround times for diagnostic tests, including imaging, biopsies, and molecular analyses. Their close collaboration with clinicians facilitates seamless patient care, making them a preferred choice for accurate and well-timed lung cancer analysis and treatment planning.

Lung Cancer Diagnostics Market Overview by Regions

By country, the global lung cancer diagnostics market is divided into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, the Netherlands, and Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, and New Zealand), Latin America (Brazil, Mexico, and Argentina), Middle East & Africa (South Africa, Saudi Arabia, and the UAE). The United States might stay dominant in the global lung cancer diagnostics market. 

United States Lung Cancer Diagnostics Market

Rising lung cancer incidence, improvements in diagnostic technology, and growing awareness of early detection are all contributing factors to the continuous expansion of the US lung cancer diagnostics market. The high rate of smoking, environmental problems including air pollution, and an aging population all have a big impact on the industry. Important diagnostic tools including liquid biopsies, PET scans, CT scans, and next-generation sequencing (NGS) are improving precision, facilitating early identification, and bolstering individualized treatment plans. The industry is growing as a result of government measures, such as screening programs for high-risk groups. Notwithstanding the advancements, issues including exorbitant diagnostic expenses, restricted insurance coverage, and unequal access to screening continue to exist. Nonetheless, the United States continues to lead the lung cancer diagnostics industry thanks to ongoing innovation and better access to healthcare.

Agilent Technologies Inc. and Quest Diagnostics teamed together in January 2023 to make the Resolution ctDx FIRST test more accessible. The test aids in the identification of patients with advanced NSCLC.

Germany Lung Cancer Diagnostics Market

The rising prevalence of lung cancer, which is fueled by factors including smoking, air pollution, and an aging population, is driving growth in the lung cancer diagnostics market in Germany. Improving survival rates requires early detection, and Germany's sophisticated healthcare system encourages the use of state-of-the-art diagnostic tools. Advanced techniques like liquid biopsy and next-generation sequencing (NGS), in addition to essential technologies like CT and PET scans, are improving diagnostic precision and facilitating individualized therapy regimens. Market expansion is also fueled by government-sponsored screening initiatives for high-risk populations. But there are also issues like exorbitant prices, the requirement for more extensive screening, and guaranteeing equitable access to cutting-edge diagnostic equipment. Germany is still at the forefront of deploying cutting-edge lung cancer diagnostic technologies throughout Europe in spite of these challenges.

China Lung Cancer Diagnostics Market

The market for lung cancer diagnostics in China is expanding quickly due to the increased incidence of lung cancer, which is mostly caused by smoking, air pollution, and an aging population. China, the most populous nation in the world, has a high cancer rate, which makes early detection and precise diagnosis essential. In both urban and rural healthcare settings, important diagnostic technologies like CT and PET scans, as well as cutting-edge instruments like liquid biopsies and next-generation sequencing (NGS), are becoming more and more popular. Government campaigns to raise awareness of cancer and encourage early screening are also propelling market expansion. Full market potential is, however, hampered by issues including exorbitant prices, unequal access to cutting-edge diagnostic tools, and inadequate healthcare facilities in rural areas. China continues to be a vital Asian market for lung cancer diagnostics in spite of these challenges.

Saudi Arabia Lung Cancer Diagnostics Market

The market for lung cancer diagnostics in Saudi Arabia is expanding because to rising cancer rates, particularly lung cancer, which are associated with smoking, air pollution, and an aging population. Enhancing healthcare access, early diagnosis, and cutting-edge treatment choices are priorities of the Kingdom's Vision 2030 healthcare programs. Because they provide greater accuracy and early-stage detection, technologies including liquid biopsies, PET imaging, and CT scans are becoming more used in diagnostic settings. The market is growing as a result of government-sponsored awareness campaigns and screening initiatives for high-risk groups. Nonetheless, issues including the high price of sophisticated diagnostic equipment, restricted access in remote locations, and the requirement for more infrastructure development in the healthcare sector continue to exist. The market for lung cancer diagnostics in Saudi Arabia is expanding despite these obstacles as healthcare modernization advances.

Lung Cancer Diagnostics Market Segments

Diagnosis Test Type – Market breakup in 5 viewpoints:

1.    Imaging Test
2.    Biopsy
3.    Sputum Cytology
4.    Molecular Test
5.    Others

Cancer Type – Market breakup in 2 viewpoints:

1.    Non- Small Cell Lung Cancer
2.    Small Cell Lung Cancer

End-User – Market breakup in 5 viewpoints:

1.    Hospital Associated Labs
2.    Independent Diagnostic Laboratories
3.    Diagnostic Imaging Centers
4.    Cancer Research Institutes
5.    Others

Country – Market breakup in 25 Countries:

1.    North America

1.1    United States
1.2    Canada

2.    Europe

2.1    France
2.2    Germany
2.3    Italy
2.4    Spain
2.5    United Kingdom
2.6    Belgium
2.7    Netherlands
2.8    Turkey

3.    Asia Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Thailand
3.6    Malaysia
3.7    Indonesia
3.8    Australia
3.9    New Zealand

4.    Latin America

4.1    Brazil
4.2    Mexico
4.3    Argentina

5.    Middle East & Africa

5.1    Saudi Arabia
5.2    UAE
5.3    South Africa

All the Key players have been covered from 3 Viewpoints:

•    Overview
•    Recent Development
•    Revenue Analysis

Company Analysis:

1.    llumina
2.    Abbott Laboratories
3.    Thermo Fisher Scientific, Inc.
4.    QIAGEN N.V.
5.    Roche Holding AG.
6.    Sanofi S.A.
7.    Agilent Technologies
8.    bioMérieux.

Report Details: